Minden

• International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Halted
  2022-500783-35-00 5 2022-12-06 Acute Myeloid Leukemia
• The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune D … Ended
  2024-518797-13-00 3 2025-07-10 systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic in
• Safety and Efficacy of intra-arterial Tenecteplase for non-complete reperfusion of intracranial occlusion Ended
  2022-502878-16-00 5 2025-01-23 Acute ischemic strokes with incomplete reperfusion
• A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic stroke Ended
  2022-501890-38-00 4 2024-02-16 acute ischemic stroke
• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 4 2023-12-06 Ulcerative Colitis
• Clinical trial of MK-7648A in adults and children with skin cancer Ended
  2022-501417-31-01 5 2023-08-01 melanoma
• A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to Evaluate the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in … Ended
  2022-500044-38-01 4 2023-02-20 Chronic Kidney Disease associated Pruritus
• Study to evaluate the efficacy and safety of fedratinib in combination with CC-486 in patients suffering from myelofibrosis in acute phase. Ended
  2024-519227-22-00 9 2022-11-03 Myeloproliferative neoplasm in accelerated phase (MPN-AP)
• Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission Ended
  2024-512856-40-00 5 2022-09-21 Giant Cell Arteritis
• A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatm … Ended
  2024-513658-31-00 4 2022-08-08 Idiopathic Sudden Sensorineural Hearing Loss
• Phase II Study of Fedratinib and Nivolumab Combination in Patients with Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor … Ended
  2024-513953-64-00 4 2022-06-23 Primary and secondary Myelofibrosis
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III … Ended
  2023-507688-20-00 5 2021-12-03 Participants with completely resected Stage III or Stage IV melanoma
• RACE-trial: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of t … Ended
  2024-516271-32-00 5 2020-06-03 Adenocarcinoma of the gastroesophageal junction (AEG type I-III)
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi … Ended
  2024-511972-33-00 5 2019-08-05 Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• HD21 Ended
  2024-518022-33-00 5 2016-07-15 Advanced Stage of Hodgkin Lymphoma

Showing 97–113 of 113 trials